{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:29:41Z","timestamp":1773674981146,"version":"3.50.1"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Chimeric antigen receptor (CAR)-based therapies have become an integral part of modern cancer care, delivering durable responses in patients with otherwise refractory hematologic malignancies. As their use has expanded, it has become increasingly clear that these immune-based treatments exert important effects on the cardiovascular system. Rather than reflecting isolated cardiac injury, CAR-associated cardiovascular complications arise from a broader inflammatory process in which immune activation, cytokine release, endothelial dysfunction, and myocardial stress are closely interconnected. Pro-inflammatory mediators such as interleukin-6, interleukin-1\u03b2, tumor necrosis factor-\u03b1, and interferon-\u03b3 play central roles in shaping these responses, particularly during cytokine release syndrome. From a clinical perspective, cardiovascular manifestations often include hypotension, arrhythmias, and transient reductions in left ventricular function, with more severe presentations occurring in patients who develop high-grade inflammatory toxicity. At the same time, advances in immune engineering are reshaping how these platforms are viewed, extending their relevance beyond toxicity alone. Preclinical studies now suggest that CAR-based approaches may be adapted to modulate cardiac fibrosis and promote myocardial repair, highlighting a potential shift from purely oncologic applications toward broader cardiovascular benefit. Placing these developments within a cardio-oncology framework emphasizes the need for careful cardiovascular assessment, longitudinal monitoring, and close collaboration between specialties.<\/jats:p>","DOI":"10.1097\/crd.0000000000001237","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:01:36Z","timestamp":1773669696000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Second-Generation and Off-the-Shelf CAR Platforms: Emerging Cardiovascular Implications of Next-Generation Cellular Immunotherapies"],"prefix":"10.1097","author":[{"given":"Jatin","family":"Thukral","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Landmark Medical Center, New York Medical College, Woonsocket, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pyush","family":"Moudgil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhay","family":"Mann","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanish","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ninaad","family":"Sindhwani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riya Kaushal","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Landmark Medical Center, New York Medical College, Woonsocket, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanishka Uttam","family":"Chandani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology-Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harbir","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hamilton Medical Center, Dalton, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Thukral","sequence":"additional","affiliation":[{"name":"Department of Occupational Therapy, Pt. Deendayal Upadhyaya National Institute for Persons with Physical Disabilities, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maharshi","family":"Raval","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston Medical Center Brighton, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth Pravin","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Landmark Medical Center, New York Medical College, Woonsocket, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"R1-20260316","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy.","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"R2-20260316","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-generation CAR T-cell therapies.","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov"},{"key":"R3-20260316","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.","volume":"17","author":"Ai","year":"2024","journal-title":"J Hematol Oncol"},{"key":"R4-20260316","doi-asserted-by":"crossref","first-page":"eabm1463","DOI":"10.1126\/scitranslmed.abm1463","article-title":"Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies.","volume":"14","author":"Goodman","year":"2022","journal-title":"Sci Transl Med"},{"key":"R5-20260316","doi-asserted-by":"crossref","first-page":"e20230903","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies.","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"R6-20260316","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/mi.2024.137","article-title":"Immune checkpoint inhibitors in metastatic melanoma therapy: a review.","volume":"4","author":"Shah","year":"2024","journal-title":"Med Int"},{"key":"R7-20260316","doi-asserted-by":"crossref","first-page":"876339","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality.","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"key":"R8-20260316","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"R9-20260316","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development.","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"key":"R10-20260316","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges.","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"R11-20260316","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","article-title":"Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms.","volume":"30","author":"Michels","year":"2022","journal-title":"Mol Ther"},{"key":"R12-20260316","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3390\/cells12121606","article-title":"Recent advances in CAR-based solid tumor immunotherapy.","volume":"12","author":"Shin","year":"2023","journal-title":"Cells"},{"key":"R13-20260316","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next?","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R14-20260316","doi-asserted-by":"crossref","first-page":"1615212","DOI":"10.3389\/fimmu.2025.1615212","article-title":"Tracing the development of CAR-T cell design: from concept to next-generation platforms.","volume":"16","author":"Alsaieedi","year":"2025","journal-title":"Front Immunol"},{"key":"R15-20260316","doi-asserted-by":"crossref","first-page":"1448752","DOI":"10.3389\/fimmu.2024.1448752","article-title":"High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-\u03b6) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy.","volume":"15","author":"Gallego-Valle","year":"2024","journal-title":"Front Immunol"},{"key":"R16-20260316","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/s41375-023-02039-z","article-title":"An \u201coff-the-shelf\u201d CD2 universal CAR-T therapy for T-cell malignancies.","volume":"37","author":"Xiang","year":"2023","journal-title":"Leukemia"},{"key":"R17-20260316","doi-asserted-by":"crossref","first-page":"e003441","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.","volume":"9","author":"Makkouk","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R18-20260316","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors.","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"R19-20260316","first-page":"557","article-title":"Next generation natural killer cells for cancer immunotherapy.","volume":"20","author":"Daher","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"R20-20260316","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy.","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"R21-20260316","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities.","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R22-20260316","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy.","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"R23-20260316","first-page":"1513","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cell therapy: a systematic review and meta-analysis.","volume":"140","author":"Alvi","year":"2019","journal-title":"Circulation"},{"key":"R24-20260316","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy.","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R25-20260316","first-page":"31","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma.","volume":"18","author":"Locke","year":"2017","journal-title":"Lancet Oncol"},{"key":"R26-20260316","first-page":"18","article-title":"Chimeric antigen receptor T-cell therapy\u2013related cardiotoxicity: a systematic review and meta-analysis.","volume":"6","author":"Ganatra","year":"2020","journal-title":"Cardio-Oncology"},{"key":"R27-20260316","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"R28-20260316","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome.","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"R29-20260316","first-page":"49","article-title":"TNF-\u03b1 in myocardial ischemia\/reperfusion injury.","volume":"106","author":"Kleinbongard","year":"2011","journal-title":"Basic Res Cardiol"},{"key":"R30-20260316","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and BBB disruption in CAR-T CRS.","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"R31-20260316","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T-cell therapy.","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"key":"R32-20260316","first-page":"3099","article-title":"Cardiotoxicity from CAR T-cell therapy.","volume":"74","author":"Totzeck","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R33-20260316","first-page":"e28162","article-title":"Cardiotoxicity associated with chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies: a systematic review.","volume":"14","author":"Hanna","year":"2022","journal-title":"Cureus"},{"key":"R34-20260316","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajem.2021.07.014","article-title":"Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.","volume":"50","author":"Lipe","year":"2021","journal-title":"Am J Emerg Med"},{"key":"R35-20260316","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11912-021-01068-0","article-title":"Cardiovascular toxicities of CAR T-cell therapy.","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"R36-20260316","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer\u2014a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-oncology.","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"R37-20260316","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s11864-023-01130-y","article-title":"Update on immunotherapy cardiotoxicity: checkpoint inhibitors, CAR T, and beyond.","volume":"24","author":"Patel","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"R38-20260316","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R39-20260316","first-page":"1613","article-title":"Immune effector cell\u2013associated cardiotoxicity.","volume":"143","author":"Ganatra","year":"2021","journal-title":"Circulation"},{"key":"R40-20260316","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Myocardial strain imaging for early detection of cardiotoxicity.","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R41-20260316","doi-asserted-by":"crossref","first-page":"A699","DOI":"10.1016\/S0735-1097(18)31240-3","article-title":"Myocarditis in immune-based therapies.","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R42-20260316","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra in patients with refractory cytokine release syndrome after CAR T-cell therapy.","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"R43-20260316","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity associated with CD19-targeted CAR-T cell therapies.","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"key":"R44-20260316","first-page":"1720","article-title":"Baseline cardiovascular risk assessment in cancer patients undergoing cardiotoxic therapies.","volume":"41","author":"Lyon","year":"2020","journal-title":"Eur Heart J"},{"key":"R45-20260316","doi-asserted-by":"crossref","first-page":"101194","DOI":"10.1016\/j.mam.2023.101194","article-title":"Cardiac fibrosis in heart failure: focus on non-invasive diagnosis and emerging therapeutic strategies.","volume":"93","author":"Ravassa","year":"2023","journal-title":"Mol Aspects Med"},{"key":"R46-20260316","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury.","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"R47-20260316","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells.","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"R48-20260316","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug.","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"R49-20260316","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/CIRCRESAHA.124.325212","article-title":"CAR-macrophage therapy alleviates myocardial ischemia-reperfusion injury.","volume":"135","author":"Wang","year":"2024","journal-title":"Circ Res"},{"key":"R50-20260316","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/CIRCRESAHA.125.326716","article-title":"CAR macrophages engineered in vivo for attenuating myocardial ischemia-reperfusion injury.","volume":"137","author":"Du","year":"2025","journal-title":"Circ Res"},{"key":"R51-20260316","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.125.076321","article-title":"Engineered regulatory T lymphocytes promote infarcted heart repair [published online ahead of print].","author":"Zhang","year":"2025","journal-title":"Circulation"},{"key":"R52-20260316","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ymthe.2025.10.003","article-title":"Innate immune cells in chimeric antigen receptor therapy.","volume":"34","author":"Jassaud","year":"2026","journal-title":"Mol Ther"},{"key":"R53-20260316","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.omto.2021.10.001","article-title":"The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy.","volume":"23","author":"Fabian","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"R54-20260316","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12967-024-06035-4","article-title":"Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells.","volume":"23","author":"Liu","year":"2025","journal-title":"J Transl Med"},{"key":"R55-20260316","doi-asserted-by":"crossref","first-page":"2275457","DOI":"10.1080\/21645515.2023.2275457","article-title":"Building safety into CAR-T therapy.","volume":"19","author":"Peters","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"R56-20260316","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","article-title":"State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses.","volume":"27","author":"Meir","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R57-20260316","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00005-023-00683-y","article-title":"In situ programming of CAR-T cells: a pressing need in modern immunotherapy.","volume":"71","author":"\u015aled\u017a","year":"2023","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"R58-20260316","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours.","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R59-20260316","doi-asserted-by":"crossref","first-page":"152479","DOI":"10.1016\/j.semarthrit.2024.152479","article-title":"Advancing autoimmune rheumatic disease treatment: CAR-T cell therapies - evidence, safety, and future directions.","volume":"67","author":"Ohno","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R60-20260316","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy.","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"R61-20260316","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3324\/haematol.2023.283848","article-title":"Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia.","volume":"109","author":"Oh","year":"2024","journal-title":"Haematologica"},{"key":"R62-20260316","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jhep.2024.01.034","article-title":"Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models.","volume":"80","author":"Dai","year":"2024","journal-title":"J Hepatol"},{"key":"R63-20260316","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis.","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R64-20260316","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1182\/bloodadvances.2025016778","article-title":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.","volume":"9","author":"Desch\u00eanes-Simard","year":"2025","journal-title":"Blood Adv"},{"key":"R65-20260316","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"key":"R66-20260316","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.","volume":"9","author":"Looka","year":"2025","journal-title":"Blood Adv"},{"key":"R67-20260316","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering.","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"R68-20260316","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors.","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:01:43Z","timestamp":1773669703000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":68,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001237","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}